The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death,...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cell and developmental biology Vol. 12; p. 1407738
Main Authors Li, Shu-Jing, Liu, An-Bu, Yu, Yuan-Yuan, Ma, Jin-Hai
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.07.2024
Subjects
caspase
Cell and Developmental Biology
gasdermin D (GSDMD)
NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome
non-alcoholic fatty liver disease (NAFLD)
pyroptosis
targeted therapy
non-alcoholic fatty liver disease (NAFLD)
gasdermin D (GSDMD)
pyroptosis
targeted therapy
NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome
caspase
Online AccessGet full text

Cover

Abstract Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
AbstractList Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can progress to end-stage liver disease in severe cases, posing a threat to life. Pyroptosis is a distinct, pro-inflammatory form of cell death, differing from traditional apoptosis. In recent years, there has been growing research interest in the association between pyroptosis and NAFLD, encompassing the mechanisms and functions of pyroptosis in the progression of NAFLD, as well as potential therapeutic targets. Controlled pyroptosis can activate immune cells, eliciting host immune responses to shield the body from harm. However, undue activation of pyroptosis may worsen inflammatory responses, induce cellular or tissue damage, disrupt immune responses, and potentially impact liver function. This review elucidates the involvement of pyroptosis and key molecular players, including NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome, gasdermin D (GSDMD), and the caspase family, in the pathogenesis and progression of NAFLD. It emphasizes the promising prospects of targeting pyroptosis as a therapeutic approach for NAFLD and offers valuable insights into future directions in the field of NAFLD treatment.
Author Yu, Yuan-Yuan
Ma, Jin-Hai
Li, Shu-Jing
Liu, An-Bu
AuthorAffiliation 2 Department of Emergency Medical , General Hospital of Ningxia Medical University , Yinchuan , Ningxia , China
1 Department of Pediatrics Medical , General Hospital of Ningxia Medical University , Yinchuan , Ningxia , China
AuthorAffiliation_xml – name: 1 Department of Pediatrics Medical , General Hospital of Ningxia Medical University , Yinchuan , Ningxia , China
– name: 2 Department of Emergency Medical , General Hospital of Ningxia Medical University , Yinchuan , Ningxia , China
Author_xml – sequence: 1
  givenname: Shu-Jing
  surname: Li
  fullname: Li, Shu-Jing
– sequence: 2
  givenname: An-Bu
  surname: Liu
  fullname: Liu, An-Bu
– sequence: 3
  givenname: Yuan-Yuan
  surname: Yu
  fullname: Yu, Yuan-Yuan
– sequence: 4
  givenname: Jin-Hai
  surname: Ma
  fullname: Ma, Jin-Hai
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39022762$$D View this record in MEDLINE/PubMed
BookMark eNpVUstO3DAUjSqqQik_0EXlJV1k6kcSJ6sKQaFIo3ZDpe6sG_t6YuSJU9uDNH_fzAMEK1_fc3Tu63wsTsYwYlF8ZnQhRNt9sxq9X3DKqwWrqJSifVeccd41ZSOqvyev4tPiIqVHSinjtaxb8aE4FR3lXDb8rEgPA5IYPBIYDVmjHmB0aU2CJdM2himH5NIem0LGMTvwJA8YYcJNdppkiCvMibiRzA2W4HUYgp8BCzlviXdPGIlxCSEhufx1dbu8-fqpeG_BJ7w4vufFn9sfD9c_y-Xvu_vrq2WpK05zKU3XA6NoGWV91c1fig0Y2zegQVSMo62lRS6ttKatpDa605xzrank2FbivLg_6JoAj2qKbg1xqwI4tU-EuFIQ5yE8KsHRoJUtCoNVU1OwwHphpaih5TXqWev7QWva9Gs0el5FBP9G9C0yukGtwpNi89ZZV--6uTwqxPBvgymrtUu7I8KIYZOUoC0XjFHezNQvr4u9VHk-20zgB4KOIaWI9oXCqNrZQ-3toXb2UEd7iP8I-LDu
Cites_doi 10.1038/s41418-023-01183-4
10.1016/j.jep.2022.115457
10.1016/j.lfs.2021.119778
10.1016/j.metabol.2021.154797
10.1084/jem.20171419
10.1097/HC9.0000000000000045
10.1155/2018/2901871
10.3390/ijms23137447
10.1016/s0966-842x(00)01936-3
10.1038/s41420-022-00859-z
10.1124/dmd.118.082008
10.1002/hep.26592
10.1016/j.jhep.2017.01.022
10.1016/j.bbrc.2020.11.009
10.3390/ijms21082790
10.1155/2018/9390786
10.3389/fimmu.2019.01309
10.1194/jlr.M085613
10.1016/j.jhep.2021.11.009
10.1038/s41418-017-0012-4
10.1016/j.molmet.2021.101270
10.1021/acs.jafc.8b00944
10.1155/2022/3711371
10.1089/met.2022.0006
10.1016/j.cellimm.2018.08.006
10.1007/s00210-019-01773-5
10.1002/jcp.27909
10.1016/j.jhep.2015.11.022
10.1002/hep4.1801
10.1016/j.biopha.2021.111504
10.1002/hep.22404
10.1038/s41598-022-26896-3
10.1371/journal.pone.0234038
10.1038/nature22393
10.1016/j.ejphar.2022.175091
10.3389/fimmu.2019.02538
10.1038/s41374-018-0177-6
10.3389/fimmu.2021.643149
10.1038/srep28734
10.3389/fimmu.2019.02926
10.1016/j.molmet.2020.101122
10.1155/2018/8597897
10.3390/biom12060824
10.1016/j.jnutbio.2019.05.015
10.1155/2020/8786424
10.1016/j.bcp.2023.115861
10.1016/j.ejphar.2019.172715
10.1016/j.jhep.2017.11.040
10.3390/md19060318
10.1016/j.envpol.2020.115655
10.1016/j.jhep.2020.04.001
10.3389/fimmu.2022.880298
10.1002/hep.30251
10.1155/2021/6659445
10.15252/embr.201948235
10.1038/s41422-019-0164-5
10.1016/j.jhep.2022.08.022
10.1002/hep.29523
10.3892/etm.2018.6300
10.3389/fphys.2021.669202
10.1007/978-981-10-8684-7_3
10.1016/j.cell.2021.04.015
10.1016/j.metabol.2014.02.003
10.1053/jhep.2003.50316
10.3390/antiox9100924
10.1016/j.jhep.2017.11.014
10.3389/fphar.2020.558525
10.1007/s00109-014-1170-1
10.3389/fimmu.2023.1113883
10.3389/fendo.2018.00640
10.1007/s11356-023-25258-4
10.1016/j.abb.2021.108894
10.1146/annurev-pathmechdis-032521-102529
10.3389/fphar.2017.00975
10.3389/fphar.2020.00185
10.3390/cells9041041
10.1097/MD.0000000000024940
10.1053/j.gastro.2005.09.004
10.1038/s41598-017-11744-6
10.1016/j.taap.2023.116424
10.1007/s10792-022-02506-z
10.1038/s41577-019-0165-0
10.1073/pnas.2000466117
10.1016/j.intimp.2020.106195
10.1126/scisignal.aax4917
10.1016/j.peptides.2020.170375
10.1016/j.jhep.2015.01.019
10.1002/j.1460-2075.1996.tb00759.x
10.3390/cells9102148
10.1038/s41586-019-1770-6
10.1016/j.biopha.2020.110542
10.3390/antiox9111040
10.1136/gutjnl-2020-322509
10.3390/ijms241713065
10.1002/jcp.28728
10.1053/j.gastro.2011.06.040
10.1038/srep24399
10.3390/ijms22136969
10.22034/IJI.2022.90579.2016
10.1111/bph.14938
10.1016/S0140-6736(15)00803-X
10.1155/2018/1864307
10.1016/j.immuni.2020.02.012
10.1016/j.ejphar.2022.175291
10.1038/s41392-021-00507-5
10.1016/j.intimp.2023.110616
10.1016/j.jcmgh.2021.04.009
10.3390/nu13030856
10.1016/j.jhep.2020.07.041
10.3760/cma.j.cn501113-20200326-00142
10.1038/358167a0
10.1002/hep.24341
10.26355/eurrev_201909_19036
10.1016/j.taap.2020.114941
10.1186/s12967-023-04380-4
10.1038/ijo.2016.74
10.1186/s12967-022-03692-1
10.3389/fnut.2023.1120254
10.1016/j.cmet.2022.05.004
10.1080/03602532.2017.1293683
10.1016/j.metabol.2020.154299
10.1155/2021/9963534
10.1073/pnas.1607769113
10.1007/s10753-017-0628-z
10.1038/s41589-019-0277-7
10.1142/S0192415X20500937
10.3389/fphar.2022.877924
10.1096/fj.201700602R
10.1038/s41419-018-1004-0
10.1016/s0966-842x(00)01945-4
10.1038/s41586-021-03478-3
10.1016/j.ijbiomac.2018.09.151
10.1016/j.ejphar.2022.175270
10.1016/j.jhep.2023.03.038
10.1038/nature10809
ContentType Journal Article
Copyright Copyright © 2024 Li, Liu, Yu and Ma.
Copyright © 2024 Li, Liu, Yu and Ma. 2024 Li, Liu, Yu and Ma
Copyright_xml – notice: Copyright © 2024 Li, Liu, Yu and Ma.
– notice: Copyright © 2024 Li, Liu, Yu and Ma. 2024 Li, Liu, Yu and Ma
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fcell.2024.1407738
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate Li et al
EISSN 2296-634X
ExternalDocumentID oai_doaj_org_article_32edef78e3de4650afa1b3f735a825ec
PMC11251954
39022762
10_3389_fcell_2024_1407738
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAYXX
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c420t-7d9ba10ef101b497d90e6adfb6aca3412ef57fe27f7fd847cdc9c222cc072e843
IEDL.DBID M48
ISSN 2296-634X
IngestDate Wed Aug 27 01:09:15 EDT 2025
Thu Aug 21 18:33:00 EDT 2025
Fri Jul 11 16:24:58 EDT 2025
Thu Apr 03 07:08:20 EDT 2025
Tue Jul 01 03:48:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords non-alcoholic fatty liver disease (NAFLD)
gasdermin D (GSDMD)
pyroptosis
targeted therapy
NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome
caspase
Language English
License Copyright © 2024 Li, Liu, Yu and Ma.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-7d9ba10ef101b497d90e6adfb6aca3412ef57fe27f7fd847cdc9c222cc072e843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Jingyue Jia Cassano, University of New Mexico, United States
Chunying Li, Georgia State University, United States
Reviewed by: Kyle Poulsen, University of Texas Health Science Center at Houston, United States
These authors have contributed equally to this work
Edited by: Emir Bozkurt, Royal College of Surgeons in Ireland, Ireland
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fcell.2024.1407738
PMID 39022762
PQID 3082311026
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_32edef78e3de4650afa1b3f735a825ec
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11251954
proquest_miscellaneous_3082311026
pubmed_primary_39022762
crossref_primary_10_3389_fcell_2024_1407738
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-03
PublicationDateYYYYMMDD 2024-07-03
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-03
  day: 03
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in cell and developmental biology
PublicationTitleAlternate Front Cell Dev Biol
PublicationYear 2024
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Ramos-Tovar (B82) 2023; 217
Flores-Costa (B32) 2020; 117
Xia (B104) 2019; 234
Younossi (B118) 2019; 69
Ying (B117) 2021; 2021
Arsenijevic (B4) 2019; 10
Wree (B101) 2018; 67
Shi (B87) 2022; 934
Zhang (B129) 2020; 2020
Papadopoulos (B77) 2022; 20
Mai (B67) 2020; 11
Zhang (B130) 2022; 933
Muriel (B72) 2021; 22
Yan (B109) 2018; 46
Liu (B60) 2019; 23
Chen (B14) 1996; 15
Pierantonelli (B80) 2017; 7
Shen (B86) 2021; 12
Cookson (B18) 2001; 9
Kugelmas (B52) 2003; 38
Xu (B107) 2018; 68
Csak (B19) 2011; 54
Zahid (B121) 2019; 10
Huang (B43) 2023; 7
Morrow (B70) 2022; 34
Swanson (B90) 2019; 19
Coll (B17) 2019; 15
Wang (B96) 2020; 177
Weng (B99) 2020; 267
Nassir (B73) 2022; 12
Gao (B37) 2023; 10
Wan (B94) 2016; 64
Zychlinsky (B135) 1992; 358
Fredrickson (B33) 2021; 53
Chen (B11) 2020; 393
Li (B56); 8
Zhang (B128); 281
Li (B54); 928
Scorletti (B84) 2022; 76
Gaul (B38) 2021; 74
Van Rooyen (B93) 2011; 141
Lin (B59) 2020; 9
Zhang (B124) 2019; 99
Zhang (B126); 705
Yu (B120) 2019; 864
Wang (B95); 13
Ding (B24) 2016; 6
Yang (B110) 2020; 21
Zheng (B131) 2018; 2018
D Souza (B26) 2001; 9
Liu (B61) 2017; 8
Zhou (B132) 2018; 9
Duan (B27) 2022; 13
Ye (B113) 2022; 296
Shi (B88) 2020; 81
Cai (B10) 2017; 40
Xiaodong (B106) 2023; 43
Koh (B50) 2021; 70
Xu (B108) 2015; 62
Han (B40) 2018; 16
Ao (B2) 2020; 133
Drummer (B25) 2023; 14
Huang (B45) 2019; 234
Kucsera (B51) 2023; 13
Kuo (B53) 2020; 9
Qiu (B81) 2018; 9
Galluzzi (B36) 2018; 25
Li (B57) 2020; 130
Zhu (B134) 2021; 12
Farrell (B30) 2018; 1061
Xia (B103) 2021; 593
Gallego (B35) 2020; 9
Lv (B65) 2019; 71
Dewidar (B23) 2020; 111
Kayagaki (B49) 2019; 12
Huang (B44) 2021; 120
Li (B55) 2023; 24
Luo (B64) 2022; 19
Rossi (B83) 2022; 23
Yu (B119) 2021; 6
Marra (B68) 2018; 68
Horn (B42) 2022; 6
Liang (B58) 2018; 2018
Biao (B9) 2022; 13
Lo (B62) 2023; 462
Bao (B6) 2020; 11
Baeza-Raja (B5) 2020; 15
Pan (B76) 2018; 332
Barnett (B7) 2020; 52
Jin (B48) 2022; 2022
Fritsch (B34) 2019; 575
Mridha (B71) 2017; 66
Loomba (B63) 2021; 184
Hwangbo (B46) 2020; 9
Ma (B66) 2022; 30
E (B29) 2023; 30
Chen (B12) 2023; 30
Henao-Mejia (B41) 2012; 482
Yang (B111) 2016; 6
Armstrong (B3) 2016; 387
Yin (B116) 2021; 2021
Dwivedi (B28) 2020; 393
Yen (B115) 2021; 138
Shi (B89) 2023; 21
Oh (B74) 2021; 19
Peng (B79) 2018; 59
Shao (B85) 2018; 2018
Zhang (B125); 12
Wang (B97); 534
Dela Peña (B21) 2005; 129
Xiao (B105) 2018; 120
De Sant Ana (B22) 2020; 10
Tang (B92) 2019; 29
Wang (B98) 2017; 547
Pafili (B75) 2021; 50
Zhang (B122); 32
Jiang (B47) 2017; 214
Wree (B100); 59
Chen (B13) 2018; 2018
Zhang (B127); 66
Aglietti (B1) 2016; 113
Feng (B31) 2022; 20
Gautheron (B39) 2020; 73
Zhang (B123) 2023; 122
Zhou (B133) 2021; 100
Yang (B112) 2014; 63
Park (B78) 2023; 78
Clément (B15) 2008; 48
Benaoudia (B8) 2019; 20
de Carvalho Ribeiro (B20) 2022; 17
Morrison (B69) 2016; 40
Yen (B114) 2020; 48
Wree (B102); 92
Tacke (B91) 2023; 79
Cobbina (B16) 2017; 49
References_xml – volume: 30
  start-page: 1829
  year: 2023
  ident: B12
  article-title: GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis
  publication-title: Cell. Death Differ.
  doi: 10.1038/s41418-023-01183-4
– volume: 296
  start-page: 115457
  year: 2022
  ident: B113
  article-title: Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis
  publication-title: J. Ethnopharmacol.
  doi: 10.1016/j.jep.2022.115457
– volume: 281
  start-page: 119778
  ident: B128
  article-title: Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2021.119778
– volume: 120
  start-page: 154797
  year: 2021
  ident: B44
  article-title: A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2021.154797
– volume: 214
  start-page: 3219
  year: 2017
  ident: B47
  article-title: Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20171419
– volume: 7
  start-page: e0045
  year: 2023
  ident: B43
  article-title: Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway
  publication-title: Hepatol. Commun.
  doi: 10.1097/HC9.0000000000000045
– volume: 2018
  start-page: 2901871
  year: 2018
  ident: B13
  article-title: NLRP3 inflammasome formation and activation in nonalcoholic steatohepatitis: therapeutic target for antimetabolic syndrome remedy FTZ
  publication-title: Oxidative Med. Cell. Longev.
  doi: 10.1155/2018/2901871
– volume: 23
  start-page: 7447
  year: 2022
  ident: B83
  article-title: The P2x7r-NLRP3 and AIM2 inflammasome platforms mark the complexity/severity of viral or metabolic liver damage
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23137447
– volume: 9
  start-page: 113
  year: 2001
  ident: B18
  article-title: Pro-inflammatory programmed cell death
  publication-title: Trends Microbiol.
  doi: 10.1016/s0966-842x(00)01936-3
– volume: 8
  start-page: 61
  ident: B56
  article-title: Downregulation of macrophage migration inhibitory factor attenuates NLRP3 inflammasome mediated pyroptosis in sepsis-induced AKI
  publication-title: Cell. Death Discov.
  doi: 10.1038/s41420-022-00859-z
– volume: 46
  start-page: 1310
  year: 2018
  ident: B109
  article-title: Glycyrrhizin alleviates nonalcoholic steatohepatitis via modulating bile acids and meta-inflammation
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.118.082008
– volume: 59
  start-page: 898
  ident: B100
  article-title: NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice
  publication-title: Hepatology
  doi: 10.1002/hep.26592
– volume: 66
  start-page: 1037
  year: 2017
  ident: B71
  article-title: NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2017.01.022
– volume: 534
  start-page: 734
  ident: B97
  article-title: NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2020.11.009
– volume: 21
  start-page: 2790
  year: 2020
  ident: B110
  article-title: Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome
  publication-title: IJMS
  doi: 10.3390/ijms21082790
– volume: 2018
  start-page: 9390786
  year: 2018
  ident: B58
  article-title: Chaihu-shugan-san decoction modulates intestinal microbe dysbiosis and alleviates chronic metabolic inflammation in NAFLD rats via the NLRP3 inflammasome pathway
  publication-title: Evid. Based Complement. Altern. Med.
  doi: 10.1155/2018/9390786
– volume: 10
  start-page: 1309
  year: 2019
  ident: B4
  article-title: Gal-3 deficiency suppresses novosphyngobium aromaticivorans inflammasome activation and IL-17 driven autoimmune cholangitis in mice
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01309
– volume: 59
  start-page: 1977
  year: 2018
  ident: B79
  article-title: Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression
  publication-title: J. Lipid Res.
  doi: 10.1194/jlr.M085613
– volume: 76
  start-page: 934
  year: 2022
  ident: B84
  article-title: A new perspective on NAFLD: focusing on lipid droplets
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2021.11.009
– volume: 25
  start-page: 486
  year: 2018
  ident: B36
  article-title: Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018
  publication-title: Cell. Death Differ.
  doi: 10.1038/s41418-017-0012-4
– volume: 53
  start-page: 101270
  year: 2021
  ident: B33
  article-title: Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH
  publication-title: Mol. Metab.
  doi: 10.1016/j.molmet.2021.101270
– volume: 66
  start-page: 4862
  ident: B127
  article-title: Amelioration of alcoholic liver steatosis by dihydroquercetin through the modulation of AMPK-dependent lipogenesis mediated by P2x7r-NLRP3-inflammasome activation
  publication-title: J. Agric. Food Chem.
  doi: 10.1021/acs.jafc.8b00944
– volume: 2022
  start-page: 3711371
  year: 2022
  ident: B48
  article-title: Dietary fatty acid regulation of the NLRP3 inflammasome via the TLR4/NF-κB signaling pathway affects chondrocyte pyroptosis
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2022/3711371
– volume: 20
  start-page: 377
  year: 2022
  ident: B77
  article-title: Nonalcoholic fatty liver disease patients exhibit reduced CD47 and increased sphingosine, cholesterol, and monocyte chemoattractant protein-1 levels in the erythrocyte membranes
  publication-title: Metab. Syndr. Relat. Disord.
  doi: 10.1089/met.2022.0006
– volume: 332
  start-page: 111
  year: 2018
  ident: B76
  article-title: Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release
  publication-title: Cell. Immunol.
  doi: 10.1016/j.cellimm.2018.08.006
– volume: 393
  start-page: 705
  year: 2020
  ident: B28
  article-title: NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway
  publication-title: Naunyn Schmiedeb. Arch. Pharmacol.
  doi: 10.1007/s00210-019-01773-5
– volume: 234
  start-page: 7885
  year: 2019
  ident: B104
  article-title: What role does pyroptosis play in microbial infection?
  publication-title: J. Cell. Physiology
  doi: 10.1002/jcp.27909
– volume: 64
  start-page: 925
  year: 2016
  ident: B94
  article-title: Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2015.11.022
– volume: 6
  start-page: 12
  year: 2022
  ident: B42
  article-title: Role of cholesterol-associated steatohepatitis in the development of NASH
  publication-title: Hepatol. Commun.
  doi: 10.1002/hep4.1801
– volume: 138
  start-page: 111504
  year: 2021
  ident: B115
  article-title: 4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2021.111504
– volume: 48
  start-page: 799
  year: 2008
  ident: B15
  article-title: Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes
  publication-title: Hepatology
  doi: 10.1002/hep.22404
– volume: 13
  start-page: 356
  year: 2023
  ident: B51
  article-title: IL-1β neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-022-26896-3
– volume: 15
  start-page: e0234038
  year: 2020
  ident: B5
  article-title: Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0234038
– volume: 547
  start-page: 99
  year: 2017
  ident: B98
  article-title: Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
  publication-title: Nature
  doi: 10.1038/nature22393
– volume: 928
  start-page: 175091
  ident: B54
  article-title: Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2022.175091
– volume: 10
  start-page: 2538
  year: 2019
  ident: B121
  article-title: Pharmacological inhibitors of the NLRP3 inflammasome
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.02538
– volume: 99
  start-page: 749
  year: 2019
  ident: B124
  article-title: Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis
  publication-title: Lab. Investig.
  doi: 10.1038/s41374-018-0177-6
– volume: 12
  start-page: 643149
  ident: B125
  article-title: Inflammasomes and fibrosis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.643149
– volume: 6
  start-page: 28734
  year: 2016
  ident: B24
  article-title: New insights into salvianolic acid A action: regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats
  publication-title: Sci. Rep.
  doi: 10.1038/srep28734
– volume: 10
  start-page: 2926
  year: 2020
  ident: B22
  article-title: Absence of the caspases 1/11 modulates liver global lipid profile and gut microbiota in high-fat-diet-induced obese mice
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.02926
– volume: 50
  start-page: 101122
  year: 2021
  ident: B75
  article-title: Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
  publication-title: Mol. Metab.
  doi: 10.1016/j.molmet.2020.101122
– volume: 2018
  start-page: 8597897
  year: 2018
  ident: B131
  article-title: Salidroside attenuates high-fat diet-induced nonalcoholic fatty liver disease via AMPK-dependent TXNIP/NLRP3 pathway
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2018/8597897
– volume: 12
  start-page: 824
  year: 2022
  ident: B73
  article-title: NAFLD: mechanisms, treatments, and biomarkers
  publication-title: Biomolecules
  doi: 10.3390/biom12060824
– volume: 71
  start-page: 110
  year: 2019
  ident: B65
  article-title: Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways
  publication-title: J. Nutr. Biochem.
  doi: 10.1016/j.jnutbio.2019.05.015
– volume: 2020
  start-page: 8786424
  year: 2020
  ident: B129
  article-title: Si-Wu-Tang alleviates nonalcoholic fatty liver disease via blocking TLR4-JNK and caspase-8-GSDMD signaling pathways
  publication-title: Evid. Based Complement. Altern. Med.
  doi: 10.1155/2020/8786424
– volume: 217
  start-page: 115861
  year: 2023
  ident: B82
  article-title: NLRP3 inflammasome in hepatic diseases: a pharmacological target
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2023.115861
– volume: 864
  start-page: 172715
  year: 2019
  ident: B120
  article-title: Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2019.172715
– volume: 68
  start-page: 773
  year: 2018
  ident: B107
  article-title: Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2017.11.040
– volume: 19
  start-page: 318
  year: 2021
  ident: B74
  article-title: Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis
  publication-title: Mar. Drugs
  doi: 10.3390/md19060318
– volume: 267
  start-page: 115655
  year: 2020
  ident: B99
  article-title: Autophagy mediates perfluorooctanoic acid-induced lipid metabolism disorder and NLRP3 inflammasome activation in hepatocytes
  publication-title: Environ. Pollut.
  doi: 10.1016/j.envpol.2020.115655
– volume: 73
  start-page: 394
  year: 2020
  ident: B39
  article-title: Lytic cell death in metabolic liver disease
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2020.04.001
– volume: 13
  start-page: 880298
  year: 2022
  ident: B27
  article-title: Association of inflammatory cytokines with non-alcoholic fatty liver disease
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2022.880298
– volume: 69
  start-page: 2672
  year: 2019
  ident: B118
  article-title: Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
  publication-title: Hepatology
  doi: 10.1002/hep.30251
– volume: 2021
  start-page: 6659445
  year: 2021
  ident: B117
  article-title: Gegen qinlian decoction ameliorates nonalcoholic fatty liver disease in rats via oxidative stress, inflammation, and the NLRP3 signal Axis
  publication-title: Evidence-Based Complementary Altern. Med.
  doi: 10.1155/2021/6659445
– volume: 20
  start-page: e48235
  year: 2019
  ident: B8
  article-title: A genome‐wide screen identifies IRF2 as a key regulator of caspase‐4 in human cells
  publication-title: EMBO Rep.
  doi: 10.15252/embr.201948235
– volume: 29
  start-page: 347
  year: 2019
  ident: B92
  article-title: The molecular machinery of regulated cell death
  publication-title: Cell. Res.
  doi: 10.1038/s41422-019-0164-5
– volume: 78
  start-page: 45
  year: 2023
  ident: B78
  article-title: IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2022.08.022
– volume: 67
  start-page: 736
  year: 2018
  ident: B101
  article-title: NLRP3 inflammasome driven liver injury and fibrosis: roles of IL-17 and TNF in mice
  publication-title: Hepatology
  doi: 10.1002/hep.29523
– volume: 16
  start-page: 1087
  year: 2018
  ident: B40
  article-title: 2,3,5,4’-tetrahydroxy-stilbene-2-O-β-D-glucoside attenuates methionine and choline-deficient diet-induced non-alcoholic fatty liver disease
  publication-title: Exp. Ther. Med.
  doi: 10.3892/etm.2018.6300
– volume: 12
  start-page: 669202
  year: 2021
  ident: B86
  article-title: Gardenoside hinders caspase-1-mediated hepatocyte pyroptosis through the CTCF/DPP4 signaling pathway
  publication-title: Front. Physiol.
  doi: 10.3389/fphys.2021.669202
– volume: 1061
  start-page: 19
  year: 2018
  ident: B30
  article-title: Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-981-10-8684-7_3
– volume: 184
  start-page: 2537
  year: 2021
  ident: B63
  article-title: Mechanisms and disease consequences of nonalcoholic fatty liver disease
  publication-title: Cell.
  doi: 10.1016/j.cell.2021.04.015
– volume: 63
  start-page: 693
  year: 2014
  ident: B112
  article-title: Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2014.02.003
– volume: 38
  start-page: 413
  year: 2003
  ident: B52
  article-title: Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E
  publication-title: Hepatology
  doi: 10.1053/jhep.2003.50316
– volume: 9
  start-page: 924
  year: 2020
  ident: B53
  article-title: Involvement of HO-1 and autophagy in the protective effect of magnolol in hepatic steatosis-induced NLRP3 inflammasome activation in vivo and in vitro
  publication-title: Antioxidants (Basel)
  doi: 10.3390/antiox9100924
– volume: 68
  start-page: 280
  year: 2018
  ident: B68
  article-title: Lipotoxicity and the gut-liver axis in NASH pathogenesis
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2017.11.014
– volume: 11
  start-page: 558525
  year: 2020
  ident: B6
  article-title: Inulin exerts beneficial effects on non-alcoholic fatty liver disease via modulating gut microbiome and suppressing the lipopolysaccharide-toll-like receptor 4-mψ-nuclear factor-κb-nod-like receptor protein 3 pathway via gut-liver Axis in mice
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.558525
– volume: 92
  start-page: 1069
  ident: B102
  article-title: NLRP3 inflammasome activation is required for fibrosis development in NAFLD
  publication-title: J. Mol. Med. Berl.
  doi: 10.1007/s00109-014-1170-1
– volume: 14
  start-page: 1113883
  year: 2023
  ident: B25
  article-title: Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2023.1113883
– volume: 9
  start-page: 640
  year: 2018
  ident: B132
  article-title: Verapamil ameliorates hepatic metaflammation by inhibiting thioredoxin-interacting protein/NLRP3 pathways
  publication-title: Front. Endocrinol. (Lausanne)
  doi: 10.3389/fendo.2018.00640
– volume: 30
  start-page: 44292
  year: 2023
  ident: B29
  article-title: Association between perfluoroalkyl substances exposure and the prevalence of nonalcoholic fatty liver disease in the different sexes: a study from the National Health and Nutrition Examination Survey 2005-2018
  publication-title: Environ. Sci. Pollut. Res. Int.
  doi: 10.1007/s11356-023-25258-4
– volume: 705
  start-page: 108894
  ident: B126
  article-title: Vitamin D ameliorates high-fat-diet-induced hepatic injury via inhibiting pyroptosis and alters gut microbiota in rats
  publication-title: Arch. Biochem. Biophys.
  doi: 10.1016/j.abb.2021.108894
– volume: 17
  start-page: 345
  year: 2022
  ident: B20
  article-title: Role of the inflammasome in liver disease
  publication-title: Annu. Rev. Pathol.
  doi: 10.1146/annurev-pathmechdis-032521-102529
– volume: 8
  start-page: 975
  year: 2017
  ident: B61
  article-title: Scutellarin suppresses NLRP3 inflammasome activation in macrophages and protects mice against bacterial sepsis
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00975
– volume: 11
  start-page: 185
  year: 2020
  ident: B67
  article-title: Berberine inhibits nod-like receptor family pyrin domain containing 3 inflammasome activation and pyroptosis in nonalcoholic steatohepatitis via the ROS/TXNIP Axis
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.00185
– volume: 9
  start-page: 1041
  year: 2020
  ident: B59
  article-title: The emerging role of MicroRNAs in NAFLD: highlight of MicroRNA-29a in modulating oxidative stress, inflammation, and beyond
  publication-title: Cells
  doi: 10.3390/cells9041041
– volume: 100
  start-page: e24940
  year: 2021
  ident: B133
  article-title: Prevalence and risk factor analysis for the nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
  publication-title: Med. Baltim.
  doi: 10.1097/MD.0000000000024940
– volume: 129
  start-page: 1663
  year: 2005
  ident: B21
  article-title: NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.09.004
– volume: 7
  start-page: 12200
  year: 2017
  ident: B80
  article-title: Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-11744-6
– volume: 462
  start-page: 116424
  year: 2023
  ident: B62
  article-title: Benzyl isothiocyanate attenuates activation of the NLRP3 inflammasome in Kupffer cells and improves diet-induced steatohepatitis
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/j.taap.2023.116424
– volume: 43
  start-page: 1405
  year: 2023
  ident: B106
  article-title: GSDMD-mediated pyroptosis in retinal vascular inflammatory diseases: a review
  publication-title: Int. Ophthalmol.
  doi: 10.1007/s10792-022-02506-z
– volume: 19
  start-page: 477
  year: 2019
  ident: B90
  article-title: The NLRP3 inflammasome: molecular activation and regulation to therapeutics
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-019-0165-0
– volume: 117
  start-page: 28263
  year: 2020
  ident: B32
  article-title: Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.2000466117
– volume: 81
  start-page: 106195
  year: 2020
  ident: B88
  article-title: Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2020.106195
– volume: 12
  start-page: eaax4917
  year: 2019
  ident: B49
  article-title: IRF2 transcriptionally induces GSDMD expression for pyroptosis
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.aax4917
– volume: 133
  start-page: 170375
  year: 2020
  ident: B2
  article-title: Liraglutide ameliorates lipotoxicity-induced inflammation through the mTORC1 signalling pathway
  publication-title: Peptides
  doi: 10.1016/j.peptides.2020.170375
– volume: 62
  start-page: 1412
  year: 2015
  ident: B108
  article-title: Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: one stone hits two birds
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2015.01.019
– volume: 15
  start-page: 3853
  year: 1996
  ident: B14
  article-title: A bacterial invasin induces macrophage apoptosis by binding directly to ICE
  publication-title: EMBO J.
  doi: 10.1002/j.1460-2075.1996.tb00759.x
– volume: 9
  start-page: 2148
  year: 2020
  ident: B35
  article-title: The absence of NLRP3-inflammasome modulates hepatic fibrosis progression, lipid metabolism, and inflammation in KO NLRP3 mice during aging
  publication-title: Cells
  doi: 10.3390/cells9102148
– volume: 575
  start-page: 683
  year: 2019
  ident: B34
  article-title: Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis
  publication-title: Nature
  doi: 10.1038/s41586-019-1770-6
– volume: 130
  start-page: 110542
  year: 2020
  ident: B57
  article-title: Role of the NLRP3 inflammasome in autoimmune diseases
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2020.110542
– volume: 9
  start-page: 1040
  year: 2020
  ident: B46
  article-title: Auranofin attenuates non-alcoholic fatty liver disease by suppressing lipid accumulation and NLRP3 inflammasome-mediated hepatic inflammation in vivo and in vitro
  publication-title: Antioxidants (Basel)
  doi: 10.3390/antiox9111040
– volume: 70
  start-page: 1954
  year: 2021
  ident: B50
  article-title: Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
  publication-title: Gut
  doi: 10.1136/gutjnl-2020-322509
– volume: 24
  start-page: 13065
  year: 2023
  ident: B55
  article-title: Research progress of pyroptosis in fatty liver disease
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms241713065
– volume: 234
  start-page: 21224
  year: 2019
  ident: B45
  article-title: Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high‐fat high cholesterol diet via regulating NF‐κB and NLRP3 inflammasome pathway
  publication-title: J. Cell. Physiology
  doi: 10.1002/jcp.28728
– volume: 141
  start-page: 1393
  year: 2011
  ident: B93
  article-title: Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.06.040
– volume: 6
  start-page: 24399
  year: 2016
  ident: B111
  article-title: A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet
  publication-title: Sci. Rep.
  doi: 10.1038/srep24399
– volume: 22
  start-page: 6969
  year: 2021
  ident: B72
  article-title: Fructose and the liver
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22136969
– volume: 19
  start-page: 4
  year: 2022
  ident: B64
  article-title: LPS activated macrophages induced hepatocyte pyroptosis via P2X7R activation of NLRP3 in mice
  publication-title: Iran. J. Immunol.
  doi: 10.22034/IJI.2022.90579.2016
– volume: 177
  start-page: 1806
  year: 2020
  ident: B96
  article-title: Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.14938
– volume: 387
  start-page: 679
  year: 2016
  ident: B3
  article-title: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)00803-X
– volume: 2018
  start-page: 1864307
  year: 2018
  ident: B85
  article-title: Exenatide delays the progression of nonalcoholic fatty liver disease in C57bl/6 mice, which may involve inhibition of the NLRP3 inflammasome through the mitophagy pathway
  publication-title: Gastroenterol. Res. Pract.
  doi: 10.1155/2018/1864307
– volume: 52
  start-page: 424
  year: 2020
  ident: B7
  article-title: Mitochondrial GSDMD pores DAMPen pyroptosis
  publication-title: Immunity
  doi: 10.1016/j.immuni.2020.02.012
– volume: 933
  start-page: 175291
  year: 2022
  ident: B130
  article-title: Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2022.175291
– volume: 6
  start-page: 128
  year: 2021
  ident: B119
  article-title: Pyroptosis: mechanisms and diseases
  publication-title: Signal Transduct. Target Ther.
  doi: 10.1038/s41392-021-00507-5
– volume: 122
  start-page: 110616
  year: 2023
  ident: B123
  article-title: MiR-223-3p attenuates radiation-induced inflammatory response and inhibits the activation of NLRP3 inflammasome in macrophages
  publication-title: Int. Immunopharmacol.
  doi: 10.1016/j.intimp.2023.110616
– volume: 12
  start-page: 653
  year: 2021
  ident: B134
  article-title: Caspase-11-Mediated hepatocytic pyroptosis promotes the progression of nonalcoholic steatohepatitis
  publication-title: Cell. Mol. Gastroenterol. Hepatol.
  doi: 10.1016/j.jcmgh.2021.04.009
– volume: 13
  start-page: 856
  ident: B95
  article-title: Ginseng saponin enriched in Rh1 and Rg2 ameliorates nonalcoholic fatty liver disease by inhibiting inflammasome activation
  publication-title: Nutrients
  doi: 10.3390/nu13030856
– volume: 74
  start-page: 156
  year: 2021
  ident: B38
  article-title: Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2020.07.041
– volume: 30
  start-page: 624
  year: 2022
  ident: B66
  article-title: Study of the effect of liraglutide on the correlation between NLRP3 inflammasome and non-alcoholic fatty liver disease
  publication-title: Zhonghua Gan Zang Bing Za Zhi
  doi: 10.3760/cma.j.cn501113-20200326-00142
– volume: 358
  start-page: 167
  year: 1992
  ident: B135
  article-title: Shigella flexneri induces apoptosis in infected macrophages
  publication-title: Nature
  doi: 10.1038/358167a0
– volume: 54
  start-page: 133
  year: 2011
  ident: B19
  article-title: Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells
  publication-title: Hepatology
  doi: 10.1002/hep.24341
– volume: 23
  start-page: 8158
  year: 2019
  ident: B60
  article-title: Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
  doi: 10.26355/eurrev_201909_19036
– volume: 393
  start-page: 114941
  year: 2020
  ident: B11
  article-title: Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/j.taap.2020.114941
– volume: 21
  start-page: 700
  year: 2023
  ident: B89
  article-title: Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-023-04380-4
– volume: 40
  start-page: 1416
  year: 2016
  ident: B69
  article-title: Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice
  publication-title: Int. J. Obes. (Lond)
  doi: 10.1038/ijo.2016.74
– volume: 20
  start-page: 497
  year: 2022
  ident: B31
  article-title: The p-STAT3/ANXA2 axis promotes caspase-1-mediated hepatocyte pyroptosis in non-alcoholic steatohepatitis
  publication-title: J. Transl. Med.
  doi: 10.1186/s12967-022-03692-1
– volume: 10
  start-page: 1120254
  year: 2023
  ident: B37
  article-title: Lycopene prevents non-alcoholic fatty liver disease through regulating hepatic NF-κB/NLRP3 inflammasome pathway and intestinal microbiota in mice fed with high-fat and high-fructose diet
  publication-title: Front. Nutr.
  doi: 10.3389/fnut.2023.1120254
– volume: 34
  start-page: 919
  year: 2022
  ident: B70
  article-title: Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
  publication-title: Cell. Metab.
  doi: 10.1016/j.cmet.2022.05.004
– volume: 49
  start-page: 197
  year: 2017
  ident: B16
  article-title: Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters
  publication-title: Drug Metab. Rev.
  doi: 10.1080/03602532.2017.1293683
– volume: 111
  start-page: 154299
  year: 2020
  ident: B23
  article-title: Metabolic liver disease in diabetes – from mechanisms to clinical trials
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2020.154299
– volume: 2021
  start-page: 9963534
  year: 2021
  ident: B116
  article-title: Jiangzhi ligan decoction inhibits GSDMD-mediated canonical/noncanonical pyroptosis pathways and alleviates high-fat diet-induced nonalcoholic fatty liver disease
  publication-title: Dis. Markers
  doi: 10.1155/2021/9963534
– volume: 113
  start-page: 7858
  year: 2016
  ident: B1
  article-title: GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1607769113
– volume: 40
  start-page: 1875
  year: 2017
  ident: B10
  article-title: NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid
  publication-title: Inflammation
  doi: 10.1007/s10753-017-0628-z
– volume: 15
  start-page: 556
  year: 2019
  ident: B17
  article-title: MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/s41589-019-0277-7
– volume: 48
  start-page: 1859
  year: 2020
  ident: B114
  article-title: Antrodia cinnamomea attenuates non-alcoholic steatohepatitis by suppressing NLRP3 inflammasome activation in vitro and in vivo
  publication-title: Am. J. Chin. Med.
  doi: 10.1142/S0192415X20500937
– volume: 13
  start-page: 877924
  year: 2022
  ident: B9
  article-title: Protective effect of danshen zexie decoction against non-alcoholic fatty liver disease through inhibition of ROS/NLRP3/IL-1β pathway by Nrf2 signaling activation
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2022.877924
– volume: 32
  start-page: 757
  ident: B122
  article-title: Silybin inhibits NLRP3 inflammasome assembly through the NAD+/SIRT2 pathway in mice with nonalcoholic fatty liver disease
  publication-title: FASEB J.
  doi: 10.1096/fj.201700602R
– volume: 9
  start-page: 946
  year: 2018
  ident: B81
  article-title: Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway
  publication-title: Cell. Death Dis.
  doi: 10.1038/s41419-018-1004-0
– volume: 9
  start-page: 112
  year: 2001
  ident: B26
  article-title: Dismantling the cryptococcus coat
  publication-title: Trends Microbiol.
  doi: 10.1016/s0966-842x(00)01945-4
– volume: 593
  start-page: 607
  year: 2021
  ident: B103
  article-title: Gasdermin D pore structure reveals preferential release of mature interleukin-1
  publication-title: Nature
  doi: 10.1038/s41586-021-03478-3
– volume: 120
  start-page: 1480
  year: 2018
  ident: B105
  article-title: Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2018.09.151
– volume: 934
  start-page: 175270
  year: 2022
  ident: B87
  article-title: Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2022.175270
– volume: 79
  start-page: 552
  year: 2023
  ident: B91
  article-title: An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2023.03.038
– volume: 482
  start-page: 179
  year: 2012
  ident: B41
  article-title: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
  publication-title: Nature
  doi: 10.1038/nature10809
SSID ssj0001257583
Score 2.288516
SecondaryResourceType review_article
Snippet Non-alcoholic fatty liver disease (NAFLD) is a clinical pathological syndrome characterized by the excessive accumulation of fat within liver cells, which can...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1407738
SubjectTerms caspase
Cell and Developmental Biology
gasdermin D (GSDMD)
NOD-like receptor thermal protein domain associated protein 3(NLRP3) inflammasome
non-alcoholic fatty liver disease (NAFLD)
pyroptosis
targeted therapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYhUMilNGnabtIUFXJIKSa2JNvyMX0soTQ5NZCbkKURXWjsJXYO--87IznBWwq99GhL2MN8I82MNA_GTqGxSpc5ZJTnmSnnZNZaVWY62NI7FJCyoHznq-vq8kZ9uy1vZ62-KCYslQdOjDuXAjyEWoP0oNCcsMEWrQy1LC06N-Bo90WdN3Om0ukKmiFapiwZ9MKa80AH4egPCoWbQ17HhJSZJooF-_9mZf4ZLDnTPssX7PlkNvKLRO4-24HugD1LjSQ3L9mAaHMKFOS28_wOKJ13NdzxPvD15r5fj_2wGuLYuh8pPgi_Ncu84ikefOCrjnd9l9nUNxcHgh3HDf9FwRt8usvhZ9cXy-9fPhyym-XXH58vs6mdQuaUyMes9k1rixwCrsJWNfiYQ2V9aCvrLCozAaGsA4g61MGj0nLeNQ7NB-fyWoBW8hXbRRrgDeNt7h1dsGqcglqw0DrkAbyURVEJaKsF-_jIWrNOVTMMehsEhIlAGALCTEAs2Cfi_tNMqngdX6AcmEkOzL_kYMHeP2JncIXQT2wH_cNgYkEetHIEkvU6Yfn0K9lQCcVKLJjeQnmLlu2RbvUzVuEuyDRsSnX0P6g_ZnvEkRgHLN-y3fH-AU7Q2hnbd1GwfwPKrgEy
  priority: 102
  providerName: Directory of Open Access Journals
Title The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD)
URI https://www.ncbi.nlm.nih.gov/pubmed/39022762
https://www.proquest.com/docview/3082311026
https://pubmed.ncbi.nlm.nih.gov/PMC11251954
https://doaj.org/article/32edef78e3de4650afa1b3f735a825ec
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1La9wwEBZpSksupe9uH0GFHlqKG1uSLflQSvpYQmly6sLejCyN2oXE3qwdyP77zsjekC3J0ZbQa2aYb6R5MPYOSqtMnkJCcZ6Jck4mtVV5YoLNvUMGyTOKdz4-KY5m6uc8n--wTbmj8QC7G007qic1W51-ujxff0GB_0wWJ-rbg0B33GjqCYVyn2otzR12FzWTpooGxyPcH-5cEJzEzJxClEVSSDUf4mhuGWaP3Zcl5dgrxJbaitn9b4Kk_3tWXlNV04fswYgx-eHAFI_YDjSP2b2h6uT6CeuQNTh5FXLbeH4GFPu76M54G_hyvWqXfdstuti2bHtyJsKxroVp8cF5vOOLhjdtk9ihyC42BNv3a35Knh58fPjh708Op7--f3jKZtMfv78dJWPthcQpkfaJ9mVtsxQCimytSvxMobA-1IV1FjWfgJDrAEIHHTxqOOdd6RBrOJdqAUbJZ2wX1wAvGK9T7-g11mAXVJmZMSEN4KXMskJAXUzYx83RVsshxUaFpgnRpIo0qYgm1UiTCftKp3_Vk9Jjxx_t6k81SlslBXgI2oD0oBCD2mCzWgYtc4sWMbgJe7uhXYXiRJPYBtqLrorZexASCVzW84GWV1NteGHCzBaVt9ay3dIs_saU3RnhyDJXL28d9BXbo21GT2D5mu32qwt4g3inr_fjPcF-ZOV_7WD-Ng
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+role+and+mechanism+of+pyroptosis+and+potential+therapeutic+targets+in+non-alcoholic+fatty+liver+disease+%28NAFLD%29&rft.jtitle=Frontiers+in+cell+and+developmental+biology&rft.au=Li%2C+Shu-Jing&rft.au=Liu%2C+An-Bu&rft.au=Yu%2C+Yuan-Yuan&rft.au=Ma%2C+Jin-Hai&rft.date=2024-07-03&rft.issn=2296-634X&rft.eissn=2296-634X&rft.volume=12&rft.spage=1407738&rft_id=info:doi/10.3389%2Ffcell.2024.1407738&rft_id=info%3Apmid%2F39022762&rft.externalDocID=39022762
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-634X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-634X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-634X&client=summon